nated [6] . When comparing cumulative incidence rates of IDDM up to 15 years of age between birth cohorts 1973, 1974 and 1976, 1977 (Fig. 1) there is clearly no significant difference. As can be seen, the cumulative incidence was slightly lower during 1974 whereas 1973, 1976 and 1977 are almost identical. Since the incidence registration of childhood diabetes started on 1 July 1977 cumulative incidence rates in children with disease onset before the age of 4 years could not be compared. The proportion of diabetic patients in these agegroups is, however, very low, between 10-15 % (e. g. 46/367 in 1977). An effect of BCG vaccination on the incidence of IDDM in very young-onset diabetic patients thus could not be excluded but would not account for a large proportion of cases.
We conclude that, on a population basis, BCG-vaccination in newborn children seems to have no significant effect on the incidence of childhood-onset IDDM and therefore would not offer an effective primary prevention strategy. Dear Sir, According to the theory of molecular mimicry as an explanation for the development of autoimmune disease, the existence of identical or very similar amino acid sequences between environmental agents (e. g. viruses) and 'self' antigens leads to the immune system cross-reacting against self antigens, hence triggering autoimmunity [1] . In view of the fact that peptides presented by HLA class II molecules are frequently ubiquitous self proteins, we have suggested that mimicry between these and motifs associated with known autoantigens could also trigger autoimmune reactions [2] . In connection with such considerations, we recently noted that a plasma protein, alpha-2-macroglobulin, contains an amino acid sequence bearing a significant homology to the two forms of glutamic acid decarboxylase (GADrs and GAD67 ) which are well-defined antigens recognised by autoantibodies in insulin-dependent diabetes melli- . These sequences are PEVKSK on alpha-2-macroglobulin and PEVKEK and PEVKTK on GAD65 and GAD67 , respectively. Moreover, the immediately succeeding sequences (AIGYL, GMAAL and GMAAV, respectively) would correspond in the main to conservative substitutions. A1-pha-2-macroglobulin is an inhibitor of low molecular weight proteases such as trypsin and plasmin [4] and its levels have been reported to be increased in diabetes [5] . These properties of alpha-2-macroglobulin, coupled with the sequence homology, raises an intriguing question of whether T-helper ceils, recognising an epitope of alpha-2-macroglobulin presented by HLA class II molecules may also, under certain conditions, respond to GAD, the autoantigen implicated in the autoimmune destruction of beta cells [6] . As an initial test of this hypothesis, we set out to determine whether sera from patients with IDDM have autoantibodies reacting with alpha-2-macroglobulin. We employed an ELISA system established and optimised using polyclonal rabbit anti-human alpha-2-macroglobulin antiserum. Microtitre plates were coated with 200 ng/ml of purified alpha-2-macroglobulin and reacted with five normal sera and ten sera from patients with high titres of anti-GAD antibodies (126 to 212 arbitrary units [7] ) followed by reaction with 1 in 6000 dilution of anti-human IgG conjugated to horseradish peroxidase. The substrate used was o-phenylenediamine dihydrochloride dissolved in phosphate-citrate buffer containing sodium perborate and the optical density was read in a microplate reader at 490 rim. We found no specific reactivity of these "high titre" sera with alpha-2-macroglobulin as compared to normal sera. Pre-absorption of two sera with the highest titre of anti-GAD antibodies using 1 ~tg/ml of the pufffled alpha-2-macroglobulin did not reduce the optical density obtained and thus confirmed that no antibody cross-reactivity between GAD and alpha-2-macroglobulin could be demonstrated using our assay. We therefore conclude that most probably autoantibodies against alpha-2-macroglobulin are not present in patients with IDDM despite the fact that there exists a degree of sequence homology between alpha-2-macroglobulin and the major target antigen of this disease and the fact that alpha-2-macroglobulin levels are increased in this condition. Nevertheless, it remains to be established whether the homologous sequence in alpha-2-macroglobulin is a T-cell epitope, since IDDM is a T-cell mediated autoimmune disease Reply to Norammi et al.
Dear Sir, The letter from Norazmi et al. points to a remarkable homology in amino acid sequence between a normal plasma protein, alpha-2-macroglobulin, and the two isoforms of glutamic acid decarboxylase (GAD), an enzyme which has been proposed as the autoantigen that "drives" the autoimmune attack on islet beta cells. The implication of the sequence homology is based on a variant of the molecular mimicry hypothesis recently elaborated by the authors [1] . No objection can be raised against the sequence homology which is clear both for the hexapeptide proposed and for the flanking sequences. However, to hold this homology responsible for the triggering of autoimmune responses leading to insulin-dependent diabetes mellitus would imply a series of immune deviations which in our opinion are improbable: 1) Development of tolerance to ubiquitous autologous proteins is assumed to be a default mechanism both for B cells in bone marrow and for T cells in the thymus. T-cell autoreactivity to peptides which normally occupy the presenting cavities of HLA molecules in antigen presenting cells (APCs) would be prevented because -being ubiquitous -they should be presented by thymic dendritic cells and T cells capable of recognizing them would be duly deleted. A failure in this process leading to the escape to periphery of T cells reacting to such common antigens can only be due to a central defect in T-cell development and the expected results would be a lupus-like situation as seen in the lpr mice who have a defect in apoptosis is an inefficient mode of entry into the class II antigen processing pathway. Effective presentation of antigens will depend on endocytosis after binding to a cell surface receptor that is selectively expressed on APCs. It is therefore unlikely than a normal plasma protein would be actively presented in the periphery. Moreover, when presenting cells become activated one would expect that normal peptides present in "quiescent" APC would be displaced by peptides derived from processing of foreign antigens [3] . 3) Nevertheless, if alpha-2-macroglobulin reactive T cells would escape to the periphery and they happen to encounter appropriate presentation of the relevant peptide, the most unlikely target cells would then be the pancreatic beta cells. For that to happen we would have to assume a microenvironment which specifically favours the recruitment of enough T cells to the pancreas in addition to providing appropriate antigen presenting conditions in the site. 4) Once we have the peptide-specific T cells in the pancreas, GAD peptide recognition should then lead to destruction of beta cells. However, we have found that GAD is also expressed in the alpha and delta cells of the pancreatic islets [4] which are not destroyed in the diabetic process. In addition to that, we have also observed that GAD remains expressed in the islets of diabetic patients even 10 years after the clinical onset of the disease and that occurs without any persisting sign of inflammation or autoimmune attack [5] .
We therefore consider the antigen mimicry between self molecules as an unlikely cause of autoimmunity. In any case a more localized event such as beta cell specific virus infection should happen at the same time for the proposed mechanism to have some probability of occurring. We also tend to believe that immunization to GAD may be, at least in humans, a secondary phenomenon, as are many humoral autoimmune responses.
Sincerely yours, R. Pujol-Borrell, D. Jaraquemada P6rez de Guzman
